Pfizer
Pfizer forecasts 2026 profit below expectations on lower Covid product sales
Pfizer has rolled out a sweeping cost reduction programme in response to the drop in Covid-19 sales
Pfizer looks to sell stake in pandemic vaccine partner BioNTech
The stake sale could be worth about US$508 million for Pfizer
Metsera accepts Pfizer’s US$10 billion bid in ongoing M&A battle
OBESITY drug developer Metsera said on Friday that it had accepted Pfizer’s US$10 billion acquisition offer, in what could spell the end of a bidding war between the New York-based pharma giant and ri...
Pfizer boosts profit view as it battles for obesity startup
Its adjusted earnings for the year will be US$3 a share to US$3.15 a share
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
[BENGALURU] Pfizer on Friday (Oct 31) filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s US$8.5 billion bid ...
The Pfizer-Trump deal: A new chapter in drug pricing or political theatre?
The approach may generate headlines while leaving the structural problems of American pharmaceutical pricing unaddressed
Pfizer’s drug price cuts yield three-year Trump tariff reprieve
The US president has repeatedly pressured companies to bring their US prices in line with what foreign countries pay
Why China biotech is getting a DeepSeek moment, too
The country is emerging as an attractive place for Big Pharma to chase billion-dollar licensing deals
Pfizer sells entire Haleon stake for US$3.24 billion
The total sale represents 7.3% of the issued share capital of Haleon
Pfizer's Covid-19 drug powers strong quarterly profit as activist hovers
Sales of its Covid-19 treatment Paxlovid blew past Wall Street expectations
